^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TCR modulator

    Related drugs:
    2d
    Advances in cell therapy for solid tumours: European perspective and future directions. (PubMed, Lancet Reg Health Eur)
    The recent US FDA approvals of lifileucel (a TIL therapy for advanced melanoma) and afamitresgene autoleucel (a TCR therapy targeting MAGE-A4 in synovial sarcoma) mark the first regulatory recognition of cell therapies for solid tumours and signal a new era for oncology...Emphasis is placed on emerging innovations like gene-edited and allogeneic therapies, as well as future directions for integrating cell therapies into mainstream oncology. We conclude with recommendations for overcoming barriers related to cost, toxicity management, and equitable access across Europe.
    Review • Journal
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Tecelra (afamitresgene autoleucel) • Amtagvi (lifileucel)
    4d
    Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation (clinicaltrials.gov)
    P1, N=19, Recruiting, BlueSphere Bio, Inc
    New P1 trial
    |
    NPM1 (Nucleophosmin 1)
    |
    NPM1 mutation
    23d
    IMA401-101: IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor (clinicaltrials.gov)
    P1, N=95, Active, not recruiting, Immatics Biotechnologies GmbH | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2025 --> Mar 2026
    Enrollment closed • Trial primary completion date • Checkpoint inhibition • First-in-human
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    Keytruda (pembrolizumab) • IMA401
    1m
    ALLOHA: A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation (clinicaltrials.gov)
    P1, N=75, Recruiting, TScan Therapeutics, Inc. | Trial primary completion date: Dec 2025 --> Jun 2026
    Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    melphalan • TSC-100 • TSC-101
    1m
    PNOC018: Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    H3.3K27M
    |
    cyclophosphamide • fludarabine IV • KIND T
    2ms
    RPTR-1-201-101: An early phase trial of RPTR-1-201 in Advanced Solid Tumors (2025-524010-28-00)
    P1/2, N=52, Not yet recruiting, Repertoire Immune Medicines Inc.
    New P1/2 trial
    |
    Keytruda (pembrolizumab)
    2ms
    TITAN: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. (clinicaltrials.gov)
    P1, N=72, Recruiting, AstraZeneca | N=32 --> 72
    Enrollment change
    2ms
    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, USWM, LLC (dba US WorldMeds) | Trial completion date: Jul 2025 --> Jul 2026
    Trial completion date
    |
    CTAG1B (Cancer/testis antigen 1B)
    |
    cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)
    2ms
    Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=108, Recruiting, AstraZeneca | N=24 --> 108
    Enrollment change
    |
    KRAS (KRAS proto-oncogene GTPase) • HLA-A (Major Histocompatibility Complex, Class I, A) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    KRAS mutation • KRAS G12D • KRAS G12
    2ms
    Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd.
    New P1 trial
    2ms
    An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    2ms
    A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases (clinicaltrials.gov)
    P1, N=18, Recruiting, China Immunotech (Beijing) Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open